CA2894381C - Multiplex nucleic acid detection methods - Google Patents
Multiplex nucleic acid detection methods Download PDFInfo
- Publication number
- CA2894381C CA2894381C CA2894381A CA2894381A CA2894381C CA 2894381 C CA2894381 C CA 2894381C CA 2894381 A CA2894381 A CA 2894381A CA 2894381 A CA2894381 A CA 2894381A CA 2894381 C CA2894381 C CA 2894381C
- Authority
- CA
- Canada
- Prior art keywords
- probe
- nucleic acids
- target nucleic
- different
- amplicons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 79
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 70
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 70
- 238000001514 detection method Methods 0.000 title claims abstract description 39
- 239000000523 sample Substances 0.000 claims abstract description 150
- 238000000034 method Methods 0.000 claims abstract description 53
- 238000007838 multiplex ligation-dependent probe amplification Methods 0.000 claims abstract description 30
- 238000009396 hybridization Methods 0.000 claims abstract description 24
- 108091093088 Amplicon Proteins 0.000 claims abstract description 23
- 238000012163 sequencing technique Methods 0.000 claims abstract description 20
- 230000000295 complement effect Effects 0.000 claims description 23
- 102000003960 Ligases Human genes 0.000 claims description 19
- 108090000364 Ligases Proteins 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 14
- 238000003786 synthesis reaction Methods 0.000 claims description 11
- 230000011987 methylation Effects 0.000 claims description 8
- 238000007069 methylation reaction Methods 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 description 40
- 239000002773 nucleotide Substances 0.000 description 33
- 238000003752 polymerase chain reaction Methods 0.000 description 18
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 13
- 108700024394 Exon Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 101150015424 dmd gene Proteins 0.000 description 12
- 230000037452 priming Effects 0.000 description 11
- 230000003321 amplification Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000005251 capillar electrophoresis Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 102000012410 DNA Ligases Human genes 0.000 description 6
- 108010061982 DNA Ligases Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- -1 carbocyclic sugars Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
- 108091029523 CpG island Proteins 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 108091007743 BRCA1/2 Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 206010069382 Hereditary neuropathy with liability to pressure palsies Diseases 0.000 description 1
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 description 1
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 102100021947 Survival motor neuron protein Human genes 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 108700029631 X-Linked Genes Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003290 ribose derivatives Chemical group 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734838P | 2012-12-07 | 2012-12-07 | |
| US61/734,838 | 2012-12-07 | ||
| PCT/US2013/073745 WO2014089536A1 (en) | 2012-12-07 | 2013-12-06 | Multiplex nucleic acid detection methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2894381A1 CA2894381A1 (en) | 2014-06-12 |
| CA2894381C true CA2894381C (en) | 2021-01-12 |
Family
ID=50884061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2894381A Active CA2894381C (en) | 2012-12-07 | 2013-12-06 | Multiplex nucleic acid detection methods |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9624533B2 (enExample) |
| EP (1) | EP2929044B1 (enExample) |
| JP (1) | JP6484177B2 (enExample) |
| CN (1) | CN104995309B (enExample) |
| BR (1) | BR112015013234B1 (enExample) |
| CA (1) | CA2894381C (enExample) |
| CL (1) | CL2015001568A1 (enExample) |
| HK (1) | HK1216653A1 (enExample) |
| IL (1) | IL239258B (enExample) |
| WO (1) | WO2014089536A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3968023B1 (en) | 2013-08-19 | 2025-10-08 | Invitae Corporation | Assays for single molecule detection and use thereof |
| WO2016070164A1 (en) * | 2014-11-01 | 2016-05-06 | Singular Bio, Inc. | Assays for single molecule detection and use thereof |
| CN113528623A (zh) * | 2015-02-18 | 2021-10-22 | 卓异生物公司 | 用于单分子检测的测定及其应用 |
| CN107083427B (zh) * | 2016-04-01 | 2021-07-30 | 广州市基准医疗有限责任公司 | Dna连接酶介导的dna扩增技术 |
| US11702702B2 (en) | 2016-04-15 | 2023-07-18 | Predicine, Inc. | Systems and methods for detecting genetic alterations |
| US11174503B2 (en) | 2016-09-21 | 2021-11-16 | Predicine, Inc. | Systems and methods for combined detection of genetic alterations |
| CA3048420C (en) * | 2016-12-09 | 2025-05-20 | Boreal Genomics Inc | Linked ligation |
| WO2018127408A1 (en) * | 2017-01-05 | 2018-07-12 | Tervisetehnoloogiate Arenduskeskus As | Quantifying dna sequences |
| US20180237853A1 (en) * | 2017-02-19 | 2018-08-23 | Yan Wang | Methods, Compositions and Kits for Detection of Mutant Variants of Target Genes |
| CN107177693B (zh) * | 2017-07-19 | 2020-11-06 | 中山大学 | 一种多倍pcr扩增方法 |
| WO2019046768A1 (en) * | 2017-08-31 | 2019-03-07 | William Marsh Rice University | SYMBOLIC SEQUENCING OF DNA AND RNA BY SEQUENCE CODING |
| CN110656159B (zh) * | 2018-06-28 | 2024-01-09 | 深圳华大生命科学研究院 | 一种拷贝数变异的检测方法 |
| EP3830828A4 (en) * | 2018-07-27 | 2022-05-04 | Myriad Women's Health, Inc. | METHODS FOR DETECTING GENETIC VARIATIONS IN HIGHLY HOMOLOGOUS SEQUENCES BY INDEPENDENT ALIGNMENT AND PAIRING OF SEQUENCE READS |
| CN109402232A (zh) * | 2018-10-23 | 2019-03-01 | 中国农业大学 | 一种用于检测的组合物及检测方法 |
| US20220290242A1 (en) * | 2018-11-05 | 2022-09-15 | Centre Henri Becquerel | Method for diagnosing a cancer and associated kit |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5508179A (en) | 1994-03-18 | 1996-04-16 | Bio-Rad Laboratories, Inc. | Use of deoxyribose nicotinamide adenine dinucleotide to enhance the specificity of NAD+ -dependent ligation reactions |
| EP2369007B1 (en) * | 1996-05-29 | 2015-07-29 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| US6544732B1 (en) | 1999-05-20 | 2003-04-08 | Illumina, Inc. | Encoding and decoding of array sensors utilizing nanocrystals |
| GB0400584D0 (en) | 2004-01-12 | 2004-02-11 | Solexa Ltd | Nucleic acid chacterisation |
| SE0401270D0 (sv) | 2004-05-18 | 2004-05-18 | Fredrik Dahl | Method for amplifying specific nucleic acids in parallel |
| JP5237126B2 (ja) * | 2006-03-01 | 2013-07-17 | キージーン ナムローゼ フェンノートシャップ | ライゲーションアッセイを用いてハイスループットシークエンスに基づき遺伝子関連配列を検出する方法 |
| US8852864B2 (en) * | 2008-01-17 | 2014-10-07 | Sequenom Inc. | Methods and compositions for the analysis of nucleic acids |
| CA2757300C (en) * | 2009-04-01 | 2018-01-09 | Dxterity Diagnostics Incorporated | Chemical ligation dependent probe amplification (clpa) |
| WO2011071923A2 (en) * | 2009-12-07 | 2011-06-16 | Illumina, Inc. | Multi-sample indexing for multiplex genotyping |
| WO2011091106A2 (en) * | 2010-01-22 | 2011-07-28 | The Regents Of The University Of California | Compositions and methods for gene signature - based chemical screening |
| US20130225420A1 (en) * | 2010-08-02 | 2013-08-29 | The Regents Of The University Of California | Molecular subtyping of oral squamous cell carcinoma to distinguish a subtype that is unlikely to metastasize |
| KR102085242B1 (ko) * | 2011-05-17 | 2020-03-05 | 디엑스테리티 다이아그노스틱스 인코포레이티드 | 표적 핵산 검출을 위한 방법 및 조성물 |
-
2013
- 2013-12-06 US US14/099,821 patent/US9624533B2/en active Active
- 2013-12-06 WO PCT/US2013/073745 patent/WO2014089536A1/en not_active Ceased
- 2013-12-06 EP EP13860702.3A patent/EP2929044B1/en active Active
- 2013-12-06 CN CN201380072327.3A patent/CN104995309B/zh active Active
- 2013-12-06 CA CA2894381A patent/CA2894381C/en active Active
- 2013-12-06 BR BR112015013234-0A patent/BR112015013234B1/pt active IP Right Grant
- 2013-12-06 HK HK16104628.4A patent/HK1216653A1/zh unknown
- 2013-12-06 JP JP2015545900A patent/JP6484177B2/ja active Active
-
2015
- 2015-06-05 CL CL2015001568A patent/CL2015001568A1/es unknown
- 2015-06-07 IL IL239258A patent/IL239258B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP6484177B2 (ja) | 2019-03-13 |
| CA2894381A1 (en) | 2014-06-12 |
| US9624533B2 (en) | 2017-04-18 |
| CL2015001568A1 (es) | 2016-08-26 |
| BR112015013234A2 (pt) | 2018-02-06 |
| EP2929044A4 (en) | 2016-07-13 |
| CN104995309A (zh) | 2015-10-21 |
| US20140235470A1 (en) | 2014-08-21 |
| JP2016500257A (ja) | 2016-01-12 |
| EP2929044A1 (en) | 2015-10-14 |
| IL239258A0 (en) | 2015-07-30 |
| EP2929044B1 (en) | 2019-02-06 |
| CN104995309B (zh) | 2020-12-08 |
| WO2014089536A1 (en) | 2014-06-12 |
| HK1216653A1 (zh) | 2016-11-25 |
| BR112015013234B1 (pt) | 2021-12-21 |
| IL239258B (en) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2894381C (en) | Multiplex nucleic acid detection methods | |
| US12077811B2 (en) | Compositions of toehold primer duplexes and methods of use | |
| US11851703B2 (en) | Methods and compositions for multiplex PCR | |
| US10072287B2 (en) | Methods of targeted sequencing | |
| EP2966180B1 (en) | Methods and compositions for multiplex pcr | |
| US20130059738A1 (en) | Methods and compositions for multiplex pcr | |
| EP2130927A1 (en) | Method for amplification of dna fragment | |
| KR102079963B1 (ko) | 소거 프로브 기반 염색체 수적이상 검출방법 및 염색체 수적이상 검출용핵산의 조성물 | |
| Dahl et al. | Methods for detection of subtle mutations in cancer genomes | |
| HK1188261B (en) | Compositions of toehold primer duplexes and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20181029 |